Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Should patients with low-risk myelodysplastic syndrome be treated earlier in the course of their disease?

Feldman EJ.

Curr Hematol Malig Rep. 2011 Mar;6(1):1-2. doi: 10.1007/s11899-010-0072-8. No abstract available.

PMID:
21161616
2.

CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.

Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A.

Clin Cancer Res. 2004 Nov 15;10(22):7599-606.

3.

Behçet disease associated with myelodysplastic syndrome.

Lin YC, Liang TH, Chang HN, Lin JS, Lin HY.

J Clin Rheumatol. 2008 Jun;14(3):169-74. doi: 10.1097/RHU.0b013e3181776bde. Review.

PMID:
18525438
4.

Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Chamuleau ME, Westers TM, van Dreunen L, Groenland J, Zevenbergen A, Eeltink CM, Ossenkoppele GJ, van de Loosdrecht AA.

Haematologica. 2009 Apr;94(4):496-506. doi: 10.3324/haematol.13612. Epub 2009 Feb 19.

5.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT)..

Haematologica. 2009 Apr;94(4):542-9. doi: 10.3324/haematol.2008.000927. Epub 2009 Mar 10.

6.

Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.

Pluta A, Kowalewski J, Kurowska M, Spiewak H, Hus M.

Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(6):787-91.

PMID:
1713883
7.

[Clinical course of severe acquired aplastic anemia to myelodysplastic syndrome and acute leukosis].

González-Barca E, Domingo A, Fernández de Sevilla A, Grañena A.

Med Clin (Barc). 1995 Jul 8;105(6):224-6. Spanish.

PMID:
7658741
8.

Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.

Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van't Veer-Korthof E, Gluckman E.

N Engl J Med. 1993 Oct 14;329(16):1152-7.

9.

The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.

Melchert M, Kale V, List A.

Curr Opin Hematol. 2007 Mar;14(2):123-9. Review.

PMID:
17255789
10.

[The myelodysplastic syndrome].

Iványi JL, Jancsik V, Kiss A, Mahunka I, Telek B, Rák K.

Orv Hetil. 1991 Jun 2;132(22):1179-84. Review. Hungarian.

PMID:
2067828
11.
12.

A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response.

Ishikawa T, Tohyama K, Nakao S, Yoshida Y, Teramura M, Motoji T, Takatoku M, Kurokawa M, Mitani K, Uchiyama T, Omine M.

Int J Hematol. 2007 Aug;86(2):150-7.

PMID:
17875530
13.

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, Hatzimichael E, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA; Hellenic MDS Study Group..

Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.

14.

A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.

Venditti A, Tamburini A, Buccisano F, Scimò MT, Del Poeta G, Maurillo L, Cox MC, Abruzzese E, Tribalto M, Masi M, Amadori S.

Ann Hematol. 2000 Mar;79(3):138-42.

PMID:
10803936
15.
16.

[Myelodysplastic syndromes--new treatment options].

Germing U.

Med Klin (Munich). 2006 Mar 22;101 Suppl 1:123-6. German.

PMID:
16802536
17.

Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes.

Schmetzer HM, Poleck B, Duell T, Gerhartz HH, Mittermüller J.

Ann Hematol. 2000 Jan;79(1):20-9.

PMID:
10663617
19.

Immunomodulatory drugs in the treatment of myelodysplastic syndromes.

Ortega J, List A.

Curr Opin Oncol. 2007 Nov;19(6):656-9. Review.

PMID:
17906467
20.

Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome.

Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T.

Br J Haematol. 1996 Apr;93(1):45-52.

PMID:
8611474

Supplemental Content

Support Center